UNCOVERING RARE OBESITY™

A GENETIC TESTING PROGRAM FOR RARE GENETIC DISEASES OF OBESITY WITH TEST COSTS COVERED BY RHYTHM PHARMACEUTICALS

Genetic testing can be an essential tool in obesity management

All obesity is not the same. Certain forms of obesity are caused by genetic variants. Genetic testing may help you and your patients understand a primary cause of their obesity by identifying relevant genetic variants.[1]

This knowledge can inform:

- Possible diagnosis
- Appropriate disease management options
- Potential eligibility for clinical studies

Clinical guidelines for the assessment, treatment, and prevention of obesity recommend genetic testing to inform diagnosis and appropriate interventions in patients with early-onset severe obesity and hyperphagia.[2,3]

Individuals with these hallmark symptoms may be eligible for a genetic test.

Eligibility

To be eligible for testing through the Uncovering Rare Obesity™ program, patients must be located in the United States, its territories, or Canada, and be:

≤18 years of age with a BMI in the **≥97th** percentile

OR

≥19 years of age with a BMI **≥40** and a history of childhood obesity

OR

An immediate family member of select, previously tested patients

OR

Showing clinical symptoms that suggest Bardet-Biedl syndrome (BBS), as the test may help provide additional evidence to support diagnosis

Visit www.preventiongenetics.com/sponsoredTesting/Rhythm/ to request a sample collection kit for your eligible patients

References: 1. Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. *Obes Facts*. 2016;9(3):158-173. **2.** Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity—assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2017;102(3):709-757. **3.** Endocrine Society experts issue clinical practice guideline on pediatric obesity. Endocrine Society. Published January 31, 2017. Accessed August 23, 2022. https://www.endocrine.org/news-and-advocacy/news-room/2017/endocrine-society-experts-issue-clinical-practice-guideline-on-pediatric-obesity.

Program details



Testing conducted by a laboratory partner

DNA testing is conducted by PreventionGenetics, a CLIA-accredited clinical laboratory.

Genetic test provides insights

The test panel includes 87 genes (29 genes associated with BBS) and 1 chromosome region, reflective of nearly all of the most frequently tested genes associated with obesity. Patients previously tested may benefit from retesting, as it could offer novel insight into their condition. The full list of genes and regions tested is available at **www.preventiongenetics.com/sponsoredTesting/Rhythm/**. This is not a test for Prader-Willi syndrome.



Multiple sample collection options

Collection kits are available for use in the office or to be sent to the patient's home. Samples may be collected in-office via OCD-100 buccal swabs. If preferred, OCD-100 buccal at-home kits are available to send directly to patients.



Easy access to test results

Test results will be available online and sent to you approximately 3 weeks after the lab receives the sample and completed forms.



Support for results interpretation

The program provides you with access to a geneticist through our partner, PreventionGenetics, to help you interpret findings and results.

Dedicated resources

Resources are available to support your ongoing educational needs following testing, including materials to help determine possible interventions. Disease education materials are also available for your patients.

UNCOVERING
RARE OBESITY™

Contacts

FOR HEALTHCARE PROVIDERS
PreventionGenetics | +1 844-513-3994
Monday–Friday, 9 AM–8 PM ET

GENERAL
UncoveringRareObesity@rhythmtx.com

CA-DSE-2300020 06/2024